STAT1 drives tumor progression in serous papillary endometrial cancer

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6519-6530

  Kharma, Budiman ^a   Baba, Tsukasa ^a   Matsumura, Noriomi ^a   Kang, Hyun Sook ^a   Hamanishi, Junzo ^a   Murakami, Ryusuke ^a   McConechy, Melissa M ^b   Leung, Samuel ^c   Yamaguchi, Ken ^a   Hosoe, Yuko ^a   Yoshioka, Yumiko ^a   Murphy, Susan K ^d   Mandai, Masaki ^e   Hunstman, David G ^b,c   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; SHORT HAIRPIN RNA; SMAD7 PROTEIN; STAT1 PROTEIN; GAMMA INTERFERON; STAT1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENICITY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ICAM 1 GENE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PD L1 GENE; SEROUS PAPILLARY ENDOMETRIAL CANCER; SMAD7 GENE; STAT1 GENE; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; CYSTADENOCARCINOMA; DISEASE COURSE; ENDOMETRIAL NEOPLASMS; MORTALITY; MOUSE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENES, MYC; HUMANS; INTERFERON-GAMMA; MICE; PROGNOSIS; STAT1 TRANSCRIPTION FACTOR;

EID: 84918574725     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0847     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Kharma B, Baba T, Mandai M, Matsumura N, Murphy SK, Kang HS, et al. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. Int J Cancer 2013;133:2234-44.
3. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
5. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997;81:228-32.
6. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228:20-30.
7. McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011;223:567-73.
8. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology 2013;62:111-23.
9. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal 2007;19:454-65.
10. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84:431-42.
11. Wang S, Raven JF, Durbin JE, Koromilas AE. Stat1 phosphorylation determines Ras oncogenicity by regulating p27 kip1. PLoS ONE 2008;3:e3476.
12. Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011;10:794-804.
13. Manavi M, Hudelist G, Fink-Retter A, Gschwandtler-Kaulich D, Pischinger K, Czerwenka K. Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol 2007;105:418-26.
14. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010;29:920-9.
15. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006;10:77-87.
16. Malilas W, Koh SS, Kim S, Srisuttee R, Cho IR, Moon J, et al. Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation. Int J Oncol 2013;43:1111-6.
17. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS ONE 2009;4:e5821.
18. Zhu H, Wang Z, Xu Q, Zhang Y, Zhai Y, Bai J, et al. Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy. Cancer Biol Ther 2012;13:401-7.
19. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci US A 2008;105:18490-5.
20. Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS ONE 2012;7:e29653.
21. Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 2007;67:9214-20.
22. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, et al. Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 2009;7:210-20.
23. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996;15:3651-8.
24. Akagami M, Kawada K, Kubo H, Kawada M, Takahashi M, Kaganoi J, et al. Transcriptional factor Prox1 plays an essential role in the antiproliferative action of interferon-gamma in esophageal cancer cells. Ann Surg Oncol 2011;18:3868-77.
25. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009;28:209-18.
26. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010;29:1741-52.
27. Yockell-Lelievre J, Spriet C, Cantin P, Malenfant P, Heliot L, De Launoit Y, et al. Functional cooperation between Stat-1 and ets-1 to optimize icam-1 gene transcription. Biochem Cell Biol 2009;87:905-18.
28. Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 2010;50:1-14.
29. Penafuerte C, Bautista-Lopez N, Bouchentouf M, Birman E, Forner K, Galipeau J. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J Immunol 2011;186:6933-44.
30. Adamkova L, Souckova K, Kovarik J. Transcription protein STAT1: biology and relation to cancer. Folia Biol 2007;53:1-6.
31. Gao B, Wang H, Lafdil F, Feng D. STAT proteins - key regulators of antiviral responses, inflammation, and tumorigenesis in the liver. J Hepatol 2012;57:430-41.
32. Adach-Kilon A, Swiatek-Machado K, Kaminska B, Dabrowski M. Signal transducer and activator of transcription 1 (Stat1) maintains basal mRNA expression of pro-survival stat3-target genes in glioma C6 cells. J Cell Biochem 2011;112:3685-94.
33. Mori S, Rempel RE, Chang JT, Yao G, Lagoo AS, Potti A, et al. Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res 2008;68:8525-34.
34. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S105-43.
35. Reardon C, McKay DM. TGF-beta suppresses IFN-gamma-STAT1-dependent gene transcription by enhancing STAT1-PIAS1 interactions in epithelia but not monocytes/macrophages. J Immunol 2007;178:4284-95.
36. Halder SK, Rachakonda G, Deane NG, Datta PK. Smad7 induces hepatic metastasis in colorectal cancer. Br J Cancer 2008;99:957-65.
37. Mhawech-Fauceglia P, Wang D, Kesterson J, Syriac S, Clark K, Frederick PJ, et al. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma. PLoS ONE 2011;6:e18066.
38. Day RS, McDade KK, Chandran UR, Lisovich A, Conrads TP, Hood BL, et al. Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinformatics 2011;12:213.
39. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013;37:874-81.
40. Perou CM, Sorlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
41. Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013;19:1363-74.
42. Hamai A, Meslin F, Benlalam H, Jalil A, Mehrpour M, Faure F, et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res 2008;68:9854-64.
43. Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol 2009;34:881-95.
44. Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, et al. Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol 2011;121:586-94.
45. Lynch RA, Etchin J, Battle TE, Frank DA. A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-gamma in human cancer cells. Cancer Res 2007;67:1254-61.
46. Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology 2013;144:1031-41 e10.
47. Usami Y, Ishida K, Sato S, Kishino M, Kiryu M, Ogawa Y, et al. Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. Int J Cancer 2013;133:568-78.
48. Wang L, Zhao Y, Liu Y, Akiyama K, Chen C, Qu C, et al. IFN-gammaand TNF-alpha synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFkappaB signaling. Stem Cells 2013;31:1383-95.
49. Matsuoka T, Adair JE, Lih FB, Hsi LC, Rubino M, Eling TE, et al. Elevated dietary linoleic acid increases gastric carcinoma cell invasion and metastasis in mice. Br J Cancer 2010;103:1182-91.